<DOC>
	<DOCNO>NCT01967537</DOCNO>
	<brief_summary>Background : - Neuroendocrine tumor ( NETs ) rare common past decade . The treatment NETs surgery , find advanced surgery . Researchers look best way find NETs earlier , surgery successful . They want test study drug use along image device detect NETs . Objectives : - To see well new experimental imaging agent , 68Gallium-DOTATATE , detect unknown primary metastatic NETs gastrointestinal system pancreas . Eligibility : - Adults 10 year old suspected NET family history NET . Design : - Participants screen medical history physical exam , blood test . - Participants undergo three scan . For , substance inject body , lie table , machine take image . &lt; TAB &gt; - A standard CT scan chest , abdomen , pelvis . &lt; TAB &gt; - An octreotide scintigraphy SPECT/CT . &lt; TAB &gt; - A 68Gallium-DOTATATE PET/CT . The study drug inject vein , usually arm . Low-dose X-rays go body . For 40 minute large , donut-shaped device take image body . The entire session take 90 120 minute . - Researchers compare image three scan . - Participants 1 follow-up visit year 5 year . At visit , medical exam , blood take , CT scan .</brief_summary>
	<brief_title>Evaluation 68Gallium-DOTATATE PET/CT Detecting Neuroendocrine Tumors</brief_title>
	<detailed_description>Background : - Neuroendocrine tumor ( NETs ) rare malignancy occur gastrointestinal tract , islet pancreas , lung , adrenal medulla thyroid C-cells . - Their incidence increase last decade , incidence 6 per 100,000 person year represent 0.46 % malignancy . - Most NETs sporadic , part familial cancer syndromes multiple endocrine neoplasia type 1 ( MEN1 ) , MEN2 , neurofibromatosis type 1 ( NF1 ) Von Hippel-Lindau ( VHL ) syndrome . - Surgical resection remain curative treatment option patient NETs 80 % patient diagnose advanced ( metastatic , locally inoperable , recurrent ) disease . - The main prognostic factor patient NET extent disease . - The best imaging technique detect unknown primary metastatic NETs yet determine . - NET cell express somatostatin receptor target radiolabeled 68Gallium-DOTATATE ( Octreotate ) imaging purpose . - The primary goal protocol determine accuracy new somatostatin receptor target imaging technique , use 68Gallium-DOTATATE PET/CT detect unknown primary metastatic NETs . Objectives : -To determine accuracy 68Gallium-DOTATATE PET/CT scan detect unknown primary metastatic gastrointestinal pancreatic neuroendocrine tumor . Eligibility : - Patients : - suspicion NET axial imaging ( CT/MRI/FDG PET ) and/or - biochemical evidence NET ( serum/urinary ) base elevated level chromogranin A , pancreatic polypeptide , neuron-specific enolase , vasoactive intestinal polypeptide , serotonin ( urinary 5-HIAA ) , gastrin , somatostatin , catecholamine , metanephrines , calcitonin , fast insulin , C-peptide ( proinsulin ) , glucagon and/or - familial predisposition NET patient MEN1 VHL . - Age great equal 18 year age . - Patients must willing return NIH follow-up . Design : - Prospective study . - A 68Ga-DOTATATE PET/CT scan do patient suspicious lesion , unknown primary tumor metastatic gastrointestinal pancreatic neuroendocrine disease find anatomic imaging ( CT/MRI ) patient biochemically active disease . - Both functional non-functional solid tumor include study . Furthermore , asymptomatic symptomatic , sporadic familial case NETs ( VHL , MEN1 ) include . - Demographic , clinical pathologic data collect medical record patient interview patient . Data store computerized database . - After initial on-study evaluation , patient stag accord finding image study respect primary tumor site , size metastasis . Surgical resection NET and/or medical management recommend base standard practice guideline . In patient undergo surgical treatment , sample immediately store molecular analysis . - Follow do yearly total duration 5 year . This include yearly image study biochemical clinical evaluation , assess tumor growth disease progression . - We estimate accrual rate 3-10 patient per month ; total accrual period study 10 month 3 year .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients ( one # 1 , # 2 , and/or # 3 ) : 1 . Suspicion NET axial imaging ( CT/MRI/FDG PET ) and/or 2. biochemical evidence neuroendocrine tumor ( serum/urinary ) base elevated level chromogranin A , pancreatic polypeptide , neuronspecific enolase , vasoactive intestinal polypeptide , serotonin ( urinary 5HIAA ) , gastrin , somatostatin , catecholamine , metanephrines , calcitonin , fast insulin , Cpeptide ( proinsulin ) , glucagon and/or 3. familial predisposition NET patient MEN1 VHL ( symptomatic and/or asymptomatic case ; biochemical anatomic imaging evidence disease ) . Age great equal 10 year age . For female : Negative urine pregnancy test OR postmenopausal least 2 year OR patient hysterectomy . Patients must willing return NIH followup . Ability subject Legally Authorized Representative ( LAR ) ( patient deem treat physician cognitively impaired questionably impaired way ability patient give inform consent questionable ) understand willingness sign write informed consent document indicate aware investigational nature study . EXCLUSION CRITERIA : Patients unwilling undergo serial noninvasive imaging . Pregnant lactating woman : Pregnant woman exclude study effect ( 68 ) GaDOTATATE pregnancy know . Because unknown potential risk adverse event nurse infant secondary administration ( 68 ) GaDOTATATE mother , breastfeed discontinue least one day mother receives ( 68 ) GaDOTATATE . Patients recognize concurrent active infection , Patients use investigational product device , exclude FDOPA scan , within 30 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 17, 2017</verification_date>
	<keyword>NET</keyword>
	<keyword>MEN1</keyword>
	<keyword>Von Hippel Lindau ( VHL )</keyword>
	<keyword>Surgical Resection</keyword>
	<keyword>Somatostatin Receptor Status</keyword>
</DOC>